UCB

cellos without players
Biotech

UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2

UCB’s Novartis-partnered oral small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2 trial.
Gabrielle Masson Dec 16, 2024 3:19pm
success failure signposts

UCB's tau drug flunks Alzheimer's trial days after Roche's exit

Nov 1, 2024 6:01am
arrow back backwards u-turn turn around reverse

Roche tosses out $120M tau prospect, returning rights to UCB

Oct 22, 2024 8:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Biogen, UCB report phase 3 lupus win after failing earlier trial

Sep 24, 2024 6:00am
ringing alarm clock times up

100 days with John Crowley: Behind BIO’s new structure & vision

Jun 25, 2024 9:05am
Handshake

Veeva, UCB link to leverage digital tools in clinical trials

May 24, 2023 3:25pm